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ABSTRACT [First-level Header] 
 
Objectives: 
Non-adherence to antihypertensive medicines limits their effectiveness, increases the risk 
of adverse health outcome and is associated with significant health care costs. The 
multiple causes of non-adherence differ both within and between patients and are 
influenced by patients’ care settings. The objective of this paper is to identify 
determinants of patient non-adherence to antihypertensive medicines, drawing from 
psychosocial and economic models of behaviour.  
Methods: 
Hypertensive outpatients from Austria, Belgium, England, Germany, Greece, Hungary, 
Netherlands, Poland and Wales were recruited to a cross-sectional online survey. Non-
adherence to medicines was assessed using the Morisky Medication Adherence Scale 
(primary outcome) and the Medication Adherence Rating Scale. Associations with 
adherence and non-adherence were tested for demographic, clinical, and psychosocial 
factors. 
Results: 
A total of 2595 patients completed the questionnaire. The percentage of patients classed 
as non-adherent ranged from 24% in the Netherlands to 70% in Hungary. Low age, low 
self-efficacy and respondents’ perceptions of their illness and cost-related barriers were 
associated with non-adherence measured on the Morisky scale across several countries. 
In multilevel, multivariate analysis, low self-efficacy (OR 0.73, 95% CI 0.70 - 0.77) and 
a high number of perceived barriers to taking medicines (OR 1.70, 95% CI 1.38 - 2.09), 
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were the main significant determinants of non-adherence. Country differences explained 
11% of the variance in non-adherence. 
Conclusions: 
Amongst the variables measured, patients’ adherence to antihypertensive medicines is 
influenced primarily by their self-efficacy, illness beliefs and perceived barriers. These 
should be targets for interventions for improving adherence, as should an appreciation of 
differences among the countries in which they are being delivered. 
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INTRODUCTION [First-level Header] 
 
 
Adherence to antihypertensive treatments is sub-optimal (1), even among patients 
participating in clinical studies, whose median persistence with medicines is only about 
one year (2). Patients who are poorly adherent (proportion of days covered ≤40%) (3) 
experience significantly increased risk of acute cardiovascular events, compared to those 
who adhere adequately (≥80%), and incur greater health care costs (4). The World Health 
Organisation (5) has called for further research to gain a better understanding of the 
determinants of non-adherence to antihypertensive medicines, and to identify common 
risk factors for non-adherence across different countries, in order to inform strategies for 
improving patient adherence. 
 
Known determinants of non-adherence to antihypertensive treatments may broadly be 
categorised to factors related to the patient (6-9) and their familial and cultural context 
(10), condition (11), treatment (8,11), socioeconomics, and health professional / health 
care system (5,12). Components of sociocognitive and self-regulatory theory including 
attitude (13), perceived behavioural control (13-14), low self-efficacy (13,15-16), lack of 
perceived treatment benefits (11), perceived barriers (7-8), illness perceptions (6,10), 
beliefs about medicines (6,11,17-18) and lack of social support (10,19-20) are 
significantly associated with non-adherence. Studies based on consumer demand theory 
support the negative impact of the costs of medicines on adherence (21), but there is a 
lack of empirical evidence on alternative behavioural economic theories such as time 
preference. We are unaware of any study in which a range of these factors has been tested 
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simultaneously to assess their combined contribution to non-adherence across several 
countries. 
 
The aim of this study, therefore, was to identify determinants of patient non-adherence to 
antihypertensive medicines, drawing from psychosocial and economic models of 
behaviour, from a cross-sectional survey across a number of European countries with 
contrasting cultures, health care systems and patient characteristics. 
 
METHODS [First-level Header] 
The research used an online, convenience cross-sectional sample of adults with 
hypertension recruited from 11 European countries. We tested the contribution of 
multiple, theory-driven determinants for association with antihypertensive treatment non-
adherence, and reported our findings according to the STROBE (STrengthening the 
Reporting of OBservational studies in Epidemiology) statement on cross-sectional studies 
(22). 
 
Procedure [Second-level Header] 
 
Following receipt of ethical approval from all relevant committees we invited 
ambulatory, adult patients with hypertension to participate in an online questionnaire. 
Patients self-selected into this study in response to advertisements placed in community 
pharmacies (Austria, Belgium, England, France, Germany, Greece, Netherlands, 
Portugal, Poland, Wales) or hypertension clinics (Hungary). Additional strategies were 
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necessary to increase recruitment in some countries. These included recruiting patients 
via general practice surgeries (Poland, Hungary), placing advertisements in the press 
(England, Wales), and using online patient support groups (Poland). No incentive was 
offered for patients to participate. The survey was administered anonymously through 
SurveyMonkey®, with one entry allowed per Internet Protocol address to reduce the 
chance of multiple responses. Patient information sheets, consent forms and eligibility 
checks, were provided online.  
 
Inclusion criteria [Second-level Header] 
 
 
We included patients who consented, and who self-reported as being: aged ≥18 years, 
diagnosed by a doctor as having hypertension that lasted at least 3 months, currently 
prescribed antihypertensive medicine(s), and personally responsible for administering 
their medicines. 
 
Exclusion criteria [Second-level Header] 
 
 
Respondents who self-reported as being diagnosed with a “psychiatric condition” or those 
living in a nursing home (or similar facility) were excluded. 
 
Potential determinants [Second-level Header] 
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Potential determinants of non-adherence were identified from published literature reviews 
(23-24). The questionnaire was developed from validated instruments, where available, 
and covered: participant demographics, use of medicines, self-rated health (25), and a 
battery of scales derived from economic (21) and sociocognitive (23-24) theories.  
 
Affordability and cost-related behaviours were assessed by a dichotomous question 
asking whether respondents had to think about the money available to spend when 
obtaining their medicines and six related items, each measured on a 5-point Likert scale 
(26). Components of the European Social Survey (27) assessed household income: 
participants reported their main source of income, their total annual income (in bands), 
whether they were coping with their present income and the ease or difficulty in 
borrowing money when in need. We assessed participants’ time preference for near, 
versus distant enjoyment of health benefits (28). The internationally standardised 
EUROPEP measure (29) assessed participants’ evaluations of the health care they 
receive. 
 
Validated, self-report tools were used to assess personal and socio-cognitive determinants 
of non-adherence. Dispositional optimism was measured using the Life Orientation Test 
(LOT-R) on 5-point Likert scales (30). Illness representations were measured using the 
Brief Illness Perception Questionnaire (B-IPQ) (31) that assessed personal beliefs about 
illness consequence, timeline, personal control, treatment control, illness identity, 
9 
 
concern about illness, illness coherence and emotional representations (the causal 
subscale was removed due to translation issues). The Beliefs about Medicines 
Questionnaire (32) assessed participants’ belief in the necessity of their medicines and 
also concerns about their medicines. Components of the Theory of Planned Behaviour 
(33-34) measured attitudes/behaviours towards taking medicines, subjective norms of 
adherence, barriers to, and facilitators of, adherence, intention to adhere and self-efficacy 
for adherence behaviours, each scored on a 5-point Likert scale. The BRIGHT 
questionnaire (35-36) was used to assess constraints/facilitators of adherence using 
subscales for barriers and social support. 
 
Outcome measures [Second-level Header] 
 
 
The primary outcome measure was self-reported non-adherence, based on the 4-item 
Morisky Medication Adherence Scale (37). This classified patients as being non-adherent 
according to a single ‘yes’ response to any of the four questions that made specific 
reference to “high blood pressure medicine”. This validated scale is the most frequently 
used questionnaire measuring adherence to medication (38). An exploratory analysis was 
also conducted of those categorised as intentionally non-adherent based on ‘yes’ 
responses to two specific Morisky items which identify non-adherence as a result of 
feeling better/worse. A secondary outcome measure of adherence was provided by the 
Medication Adherence Rating Scale (MARS) (39), which consisted of 5 items rated on a 
Likert scale with a low score (on a range of 5 - 25) indicating lower levels of adherence. 
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Our choice of outcome measures was informed by the theoretical and empirical literature 
on medication adherence spanning the behavioural and medical sciences from which the 
study questions emerged. These two conceptually different measures provided 
dichotomous data on non-adherence and continuous data on adherence to patients’ 
antihypertensive medications.  
 
The final survey had a total of 135 items. 
 
Translation [Second-level Header] 
 
 
Measures that were not validated and available in the required language were translated 
into the appropriate languages using accredited translators who were native speakers of 
the target languages and fluent in English. Translations were checked for compatibility 
with the original version in a process of back translation, performed by persons who were 
native English speakers and fluent in each target language, to ensure that none of the 
original meaning was lost. For each language, a third individual acted as a reviewer and 
highlighted any discrepancies between the forward and back translations which were 
resolved by discussion with the translators. All translations were coordinated by one 
project partner to ensure consistency. Piloting in each country enabled identification of 
any semantic inconsistencies. 
 
Sample size [Second-level Header] 
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Based on an expectation of 30% non-adherence (6) and a one-sided, 5% level of 
significance, 323 completed Morisky scores were required per country for within-country 
analyses.  
 
Data analysis [Second-level Header] 
 
 
Responses to the survey were coded in SPSS version 19 (IBM Corporation) and analysed 
in Stata version 10 (StataCorp LP). We assumed missing data to be missing at random 
and imputed using multiple imputations by chained equations (MICE) (40), to create 25 
data sets for each country. For a single incomplete variable, multiple imputation 
constructs a model relating the incomplete variable to variables in the prediction model, 
and draws from the posterior predictive distribution of the missing data, conditional on 
the observed data. Using MICE, imputed values were initialised by drawing at random 
from observed values. Imputation of missing data was performed on variables ordered by 
level of ‘missingness’, using observed and current imputed values of all predictors. To 
ensure stability, this imputation step was cycled 10 times for each of the 25 imputed data 
sets (41). Analyses were performed on each set and imputation-specific coefficients were 
pooled according to Rubin’s rules (42). Imputed data were used for all analyses with the 
exception of demographic variables where data from complete cases were used. 
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In the primary analysis, we calculated the percentage of patients classed as non-adherent 
according to Morisky score in each country. Potential associations with non-adherence 
were initially tested univariately using χ2 and independent samples t-tests (associations 
with medicines use were adjusted for age), followed by a logistic regression with non-
adherence as the dependent variable. We applied a bivariate method of selecting 
explanatory variables, whereby only variables found to be significant (p<0.05) in the 
univariate analysis were entered into the regression model based on a theoretical order 
(43-44), from determinants classified as demographic and medicines use characteristics 
(distal) to attitudes and behaviours (proximal). Assumptions regarding multicollinearity, 
singularity, normality, linearity, and homoscedasticity were tested and met. Country 
comparison analysis was conducted using χ2 tests. We adopted a similar approach for the 
secondary outcome of MARS adherence, but with a one-way ANOVA to test differences 
among countries.  
 
In order to account for variance both within-country and between-country, as a secondary 
analysis, 2-level multilevel regression models with respondents nested within country 
were specified for both Morisky (logit model) total and intentional non-adherence, and 
MARS adherence (linear regression model). Multilevel models with random intercepts 
and fixed effects were specified, initially with all variables common to all countries. Non-
contributory variables were subsequently removed iteratively, determined by highest p-
value using backwards elimination (based on p>0.05). We calculated the variance 
partition coefficient (45), to determine the attribution of country to the observed variance 
in non-adherence. 
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A complete case analysis of Morisky total non-adherence was performed to assess the 
sensitivity of our main findings to assumptions relating to missing data. In a post hoc 
analysis, we assessed the impact of excluding Hungary from the analysis, given that 
Hungary alone recruited patients from hypertension clinics. 
 
RESULTS [First-level Header] 
 
Participants: A total of 2630 adults from 11 countries completed the questionnaire. Target 
recruitment was achieved in 5 countries (Austria, England, Hungary, Poland and Wales). 
Study set-up and initiation was delayed in Belgium, Germany, Greece and The 
Netherlands leading to non-target recruitment. The analysis therefore includes these 9 
countries which each recruited over 100 participants (n=2595). There was an inadequate 
level of available research support in France and Portugal that resulted in low response 
(n=11, n=33 respectively) and these were excluded from the analysis. Included 
participants’ characteristics are presented in Table 1. The overall level of missing data by 
country ranged from 5% to 26%, with lowest rates seen on demographic and clinical 
questions (0-8%), MARS (<2%), medicine necessity and concerns (14%) and self-
efficacy (14%) and highest rates seen on the income questions (22%), time preference 
(22%) and BRIGHT barriers (23%) (Fig. 1). 
 
There were significant differences between country samples on all demographic and 
clinical characteristics assessed. Self-rated health was more often rated as poor or fair in 
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Poland (48.6%) and Hungary (47.6%) than in Belgium (16.1%), England (19.5%) and 
Wales (19.8%). Fewer respondents from Hungary, Greece and Poland had received 
higher education than in other countries. Respondents from Greece tended to be older and 
more predominantly female, and together with Hungary and Austria, had the greatest 
number of co-morbidities and were more likely to be taking medicines more frequently 
than 3 times per day. 
 
Insert Table 1 and Figure 1 
 
Prevalence of non-adherence [Second-level Header] 
 
 
Based on Morisky scores, non-adherence was least prevalent in the Netherlands, and 
most prevalent in Hungary (Table 2). Intentional non-adherence was highest in Greece. 
Polish respondents had significantly lower levels of adherence, as measured by MARS, 
than respondents from other countries. 
 
Insert Table 2 
 
Associations with Morisky non-adherence and MARS adherence [Second-level Header] 
 
 
Among demographic factors, only age showed associations across several countries with 
younger age associated with Morisky non-adherence in Austria, Belgium, Netherlands 
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and Wales (Table 3), and older age associated with MARS adherence in the Netherlands 
(Table 4). Unemployment was associated with non-adherence in England and Hungary 
only. None of the medicines-related factors showed associations with non-adherence in 
more than one country. The perceived ease or difficulty in borrowing money was 
associated with non-adherence in England and Germany and having available strategies 
to cope with the costs of medicines were significantly associated with MARS-rated 
adherence in Belgium, England, Greece and Hungary. 
 
No significant associations were evident for optimism but in contrast, beliefs about the 
illness did play a significant role. B-IPQ factors of low perceived illness consequences, 
low concern about illness, and low beliefs in personal control over illness were 
significantly associated with non-adherence on the Morisky scale in Austria, Greece 
Poland and Wales (Table 3); and high belief in treatment control, high illness coherence, 
high belief in personal control significant in Austria, Greece and Hungary based on 
MARS assessment of adherence (Table 4). Illness identity, perceived illness timeline and 
emotional representations were not significant, neither were beliefs about medicines, in 
terms of their necessity or concerns about taking them (BMQ). 
 
The socio-cognitive variables, drawn mainly from the theory of planned behaviour 
(TPB), did not emerge consistently in the inter-country analysis. Perceived barriers to 
adherence (whether changes to daily routine makes taking medicines more difficult) were 
related only to non-adherence in Greece, although a high number of barriers assessed by 
the BRIGHT (35-36) were associated with non-adherence in Austria and Poland. 
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Intention to adhere was associated with adherence in Hungary and Wales. Low self-
efficacy, however, emerged significant in relation to non-adherence in all countries 
except the Netherlands, and high self-efficacy explained adherence in all countries except 
Poland. Social support factors emerged significant only in Hungary but in a counter-
intuitive direction, in relation to low perceived environmental support and greater 
adherence. 
 
The variables examined in this study explained between 13.4% and 65.2% of the 
variability in MARS adherence (Table 4).  
 
Insert Tables 3 and 4 
 
Multilevel model [Second-level Header] 
 
 
The multilevel logit model for Morisky non-adherence identified males, being of younger 
age, being employed, low number of medicines, high dosing frequency, high normative 
beliefs, low self-efficacy, high perceived barriers, low personal control, low concern 
about illness and difficulty in borrowing money as being significantly associated with 
non-adherence (Table 5). Associations were consistent in the model specified with 
Morisky intentional non-adherence. Multilevel linear regression found older age, a lower 
level of education, a greater number of medicines, less frequent dosing, having low 
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perceived barriers, low perceptions of illness consequences, beliefs in treatment control, 
and high self-efficacy were connected to higher adherence as measured by MARS. Based 
on the Morisky scale, 11% and 7% of explained variances in total and intentional non-
adherence were attributable to differences among countries; and 23% of the variance in 
adherence based on MARS was attributable to differences among countries. 
 
Sensitivity analysis [Second-level Header] 
 
 
The analysis of complete cases resulted in less precise estimators, as expected, altering 
the significance of some variables and hence their inclusion in the final model. Self-
efficacy and perceived barriers (BRIGHT), however, remained significant as in the 
primary analysis. 
 
When Hungary was excluded from the multilevel model (due to the aforementioned 
difference in recruitment method), we observed a reduction in between-country variance 
in Morisky non-adherence (from 11% to 4%). Other factors emerged as being significant, 
including education, number of medical conditions, attitudes and intention to adhere; 
though self-efficacy and barriers remained significant. 
 
DISCUSSION [First-level Header] 
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Self-reported non-adherence to antihypertensive medicines is prevalent, even among the 
sampled population who were in receipt of a current prescription for antihypertensive 
treatment. Prevalence differs significantly across countries but while a proportion of this 
variance is explained by country-level effects and demographic characteristics, our 
principal finding is that potentially modifiable factors of low perceived self-efficacy and, 
to a lesser extent, low personal control beliefs, and high perceived barriers are 
consistently associated with non-adherence. Perceived barriers to adherence included 
forgetfulness or interruption of daily routine, practical difficulties, and feeling 
overwhelmed by circumstances or complexity of regimen. Our finding of common 
associations with non-adherence across different countries supports the importance of 
these factors, particularly given the significant differences that exist in cultural, medical 
practices and health care systems that contribute to a small proportion of the variance in 
non-adherence. 
 
Adherence is generally explained by the converse of the above but additionally, cost-
related behaviour (i.e. strategies to cope with the cost of prescriptions) and intention also 
emerged as significant in several countries. The multilevel analysis of all countries show 
that whilst many factors act in the opposite direction depending on whether we are 
addressing non-adherence or adherence, some uniquely explain non-adherence e.g. 
employment status, low normative beliefs, low personal control, low illness concern, and 
low borrowing potential; and others uniquely explain adherence e.g. lower education, low 
perceived illness consequences, (both these are counter-intuitive) and beliefs in treatment 
control. The multilevel analyses also suggest that where possible, a reduction in dose 
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frequency and number of prescribed medicines might achieve improvements in 
adherence. 
 
The literature on adherence to medicines contains many analyses that have tested the 
significance of clinical, treatment and demographic characteristics as predictors of non-
adherence, assuming that behaviour is a function of these characteristics alone. This 
approach has significant limitations. Our analysis is rooted in behavioural theories to 
reflect the notion that individual beliefs and social influences are potentially more 
relevant determinants of intentional and non-intentional non-adherence (and of 
adherence) than relatively fixed attributes of the person or their clinical situation. 
Previous studies have shown that, based on socio-cognitive and self-regulation theories, 
personal and perceived control (6,10,13,15-16), perceived benefits of treatment (7,11) 
and perceived barriers – such as forgetfulness and experienced or anticipated side effects 
(7,8) are significant predictors of non-adherence in patients taking antihypertensive 
medicines. Associations between higher levels of self-efficacy and adherence in patients 
with hypertension have been noted previously (13,46). 
 
The novelty and key strength of our study is that a range of theoretically informed factors 
derived from behavioural theories in health psychology and economics were tested 
concurrently across several European countries. Our analysis also considered the 
distinction between intentional and unintentional non-adherence. Associations with 
intentional non-adherence were fewer, and although several overlapped with those 
associated with overall non-adherence i.e. age, self-efficacy and perceived barriers, other 
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factors included the number of medical conditions, concerns about medicines, perceived 
illness identity and behavioural intention. The act of deliberately choosing to avoid taking 
medicines, therefore, warrants interventions which more explicitly target illness and 
treatment and behavioural beliefs.  
 
There are several caveats to our analysis, however, which may limit the strength of the 
interpretations. First, only five of the intended eleven countries reached target 
recruitment. We pragmatically included all 9 countries which recruited an appreciable 
number of patients, however this reduced the precision of the estimates of non-adherence 
in each country and limited the strength of inferences. Second, our analyses might be 
confounded by differences in methods of recruitment. While all countries–except 
Hungary–recruited via community pharmacies, the exclusion of Hungary from the 
secondary analysis resulted in more variables being significant. The main findings of the 
primary (per country) analysis, however, remained unchanged. Third, as responses were 
elicited via self-administered questionnaires, we had no means of confirming 
hypertension diagnosis, nor other responses, or mitigate any self-presentation bias which 
would reduce the external validity of our findings. Fourth, we were unable to assess the 
impact of non-response bias (47) as those who failed to complete the outcome measures–
which were at the beginning of the questionnaire–were not allowed to progress through 
the remainder of the survey. The length of the survey represents a fifth limitation, which 
may have impacted on completion rates. The variables ultimately emerging as being 
associated with non-adherence and adherence (i.e. TPB barriers and self-efficacy), 
however, had relatively low levels of missingness and we improved precision by 
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performing multiple imputation. While multiple imputation addresses problems in 
complete case analyses related to loss of efficiency and bias due to differences between 
observed and unobserved data, it is no substitute for a complete dataset and requires an 
important but unverifiable assumption that data are missing at random. Moreover, only 
subscale totals rather than every individual item were imputed for health psychology 
measures. This may introduce bias as data from respondents who completed some, but 
not all, of the items in a subscale were discarded. Sixth, whilst employing validated scales 
wherever possible, full testing of the BRIGHT measure did not exist at the time of the 
study. Finally, self-reported measures of adherence are prone to bias (38), and may not 
distinguish between failure to initiate dosing, incorrect implementation of the dosing 
regimen and treatment discontinuation (48). In mitigation, however, we employed two 
measures of adherence, and both had a significant association with self-efficacy.  
 
Notwithstanding these limitations, the findings can inform the development of non-
adherence reducing (or adherence-enhancing) interventions. Most importantly, the 
common variables identified within our study are amenable to change through improved 
communication with health care professionals or brief cognitive-behavioural intervention. 
Reviews of adherence-improving interventions (49-50) offer support for self-efficacy 
enhancement, with modest effects reported in trials of supportive and individually 
tailored telephone calls, information on self-management, checks on understanding and 
concerns regarding medicines and empowerment. Our analysis suggests that a 
theoretically informed, controlled trial of cognitive-behavioural interventions, focused at 
increasing self-efficacy and related control beliefs and reducing perceived barriers to 
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adherence behaviours is warranted. Given the broad spectrum of potential barriers and the 
observation of independent, country-level differences, which may be related to cultural, 
health service or other factors, interventions which are tailored specifically to the 
population in which they are being delivered are the most likely to be effective.  
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Table 1. Demographic data and cross country comparison 
 
Explanatory 
variable 
Country (number respondents) 
χ2 
p-value 
Austria 
(323) 
Belgium 
(180) 
England 
(323) 
Germany 
(274) 
Greece 
(289) 
Hungary 
(323) 
Netherlands 
(237) 
Poland 
(323) 
Wales 
(323) 
Age - mean 
(95% CI) 
60.2 
(58.8, 61.5) 
57.3 
(55.6, 59.1) 
59.6 
(58.5, 60.7) 
56.8 
(55.4, 58.2) 
63.9 
(62.6, 65.2) 
58.2 
(56.8, 59.7) 
58.3 
(57.0, 59.5) 
54.5 
(53.2, 55.8) 
61.1 
(59.9, 62.2) 
16.62 
p < 0.001 
df = 8 
Sex 
(female, %) 
145 
(44.9%) 
64 
(35.6%) 
141 
(43.7%) 
154 
(56.2%) 
173 
(59.9%) 
179 
(55.4%) 
115 
(48.5%) 
171 
(52.9%) 
119 
(36.8%) 
64.54 
p < 0.001  
df = 8 
Education 
Secondary 
only* 
120 
(37.2%) 
6 
(3.3%) 
110 
(34.1%) 
51 
(18.6%) 
148 
(51.2%) 
253 
(78.3%) 
7 
(3.0%) 
167 
(51.7%) 
98 
(30.3%) 
64.54 
p < 0.001 
df = 8 Higher 
education 
194 
(60.1%) 
174 
(96.7%) 
211 
(65.3%) 
222 
(81.0%) 
135 
(46.7%) 
68 
(21.1%) 
229 
(96.6%) 
155 
(48.0%) 
224 
(69.3%) 
Marital status 
Married 
209 
(64.7%) 
134 
(74.4%) 
241 
(74.6%) 
184 
(67.2%) 
187 
(64.7%) 
234 
(72.4%) 
186 
(78.5%) 
246 
(76.2%) 
258 
(79.9%) 
36.11 
p < 0.001 
df = 8 
Student / in 
employment 
119 
(36.8%) 
98 
(54.4%) 
166 
(51.4%) 
150 
(54.7%) 
119 
(41.2%) 
124 
(38.4%) 
151 
(63.7%) 
169 
(52.3%) 
143 
(44.3%) 
70.47 
p < 0.001 
df = 8 
Health status 
Poor 
23 
(7.1%) 
4 
(2.2%) 
10 
(3.1%) 
6 
(2.2%) 
0 
(0%) 
26 
(8.0%) 
5 
(2.1%) 
24 
(7.4%) 
13 
(4.0%) 
322.59 
p < 0.001 
df = 24 
Fair 
96 
(29.7%) 
25 
(13.9%) 
53 
(16.4%) 
84 
(30.7%) 
93 
(32.2%) 
128 
(39.6%) 
49 
(20.7%) 
133 
(41.2%) 
51 
(15.8%) 
Good 
128 
(39.6%) 
77 
(42.8%) 
123 
(38.1%) 
140 
(51.1%) 
140 
(48.4%) 
132 
(40.9%) 
112 
(47.3%) 
138 
(42.7%) 
116 
(35.9%) 
Very good 
74 
(22.9%) 
72 
(40.0%) 
137 
(42.4%) 
44 
(16.1%) 
55 
(19.0%) 
36 
(11.1%) 
69 
(29.1%) 
28 
(8.6%) 
142 
(44.0%) 
Mean number 
of medical 
conditions 
(95% CI) 
2.84 
(2.59, 3.08) 
2.29 
(2.10, 2.47) 
2.28 
(2.15, 2.42) 
2.13 
(1.97, 2.30) 
2.85 
(2.64, 3.06) 
2.85 
(2.68, 3.02) 
2.08 
(1.93, 2.24) 
2.15 
(2.02, 2.27) 
2.42 
(2.26, 2.57) 
13.16 
p < 0.001 
df = 8 
Mean number 
of medicines 
(95% CI) 
4.43 
(4.06, 4.79) 
3.54 
(3.19, 3.90) 
3.84 
(3.58, 4.10) 
3.42 
(3.14, 3.70) 
4.37 
(3.99, 4.75) 
5.17 
(4.80, 5.53) 
3.44 
(3.09, 3.79) 
4.12 
(3.83, 4.42) 
3.80 
(3.54, 4.06) 
12.01 
p < 0.001 
df = 8 
Mean units of 5.51 3.78 4.93 3.92 5.06 7.44 4.31 3.20 4.97 22.41 
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medicines per 
day (95% CI) 
(4.95, 6.07) (3.33, 4.23) (4.45, 5.40) (3.56, 4.27) (4.57, 5.54) (6.90, 7.98) (3.45, 5.16) (2.89, 3.51) (4.45, 5.49) p < 0.001 
df = 8 
Most 
frequently 
dosed 
medicine 
Once daily 
114 
(35.3%) 
123 
(68.3%) 
224 
(9.3%) 
100 
(36.5%) 
51 
(17.6%) 
54 
(16.7%) 
157 
(66.2%) 
131 
(40.6%) 
241 
(74.6%) 
557.56 
p < 0.001 
df = 16 
Twice daily 
110 
(34.1%) 
35 
(19.4%) 
63 
(19.5%) 
129 
(47.1%) 
112 
(38.8%) 
155 
(48.0%) 
56 
(23.6%) 
143 
(44.3%) 
47 
(14.6%) 
≥ Thrice daily 
96 
(29.7%) 
19 
(10.6%) 
26 
(8.0%) 
44 
(16.1%) 
123 
(42.6%) 
113 
(35.0%) 
22 
(9.3%) 
48 
(14.9%) 
35 
(10.8%) 
 
Data are counts (%), unless otherwise indicated.  
* Secondary education meaning to secondary (high) school level 
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Table 2. Prevalence of self-reported total non-adherence and intentional non-adherence across European countries based on Morisky responses, 
and adherence based on MARS 
 
 Morisky MARS 
 Respondents self-reporting as being 
non-adherent (as a percentage of all 
respondents) (95% Confidence 
Interval) 
Respondents self-reporting as being 
intentionally non-adherent (as a 
percentage of non-adherers) (95% 
Confidence Interval) 
Mean score (95% Confidence 
Interval)* 
The Netherlands 24.1 (18.6, 29.5) 21.1 (10.5, 31.6) 23.86 (23.64, 24.16) 
Germany 33.2 (27.6, 38.8) 35.2 (25.4, 45.0) 23.47 (23.28, 23.75) 
Austria 33.7 (28.6, 38.9) 51.4 (42.0, 60.8) 23.25 (23.03, 23.56) 
Wales 38.1 (32.8, 43.4) 25.2 (17.5, 32.9) 23.46 (23.30, 23.77) 
Belgium 38.9 (31.8, 46.0) 17.1 (8.3, 26.0) 23.59 (23.50, 23.99) 
England 41.5 (36.1, 46.9) 23.9 (16.7, 31.1) 23.41 (23.17, 23.65) 
Greece 50.2 (44.4, 55.9) 57.2 (49.2, 65.3) 22.08 (21.71, 22.48) 
Poland 57.6 (52.2, 63.0) 44.6 (37.5, 51.8) 18.19 (17.77, 19.01) 
Hungary 70.3 (65.3, 75.3) 18.1 (13.1, 23.1) 22.88 (22.74, 23.26) 
Cross country 
comparison 
χ2: 191.52 
df: 8 
p = 0.000 
Tests cross country difference in 
self-reported non-adherence 
χ 2: 108.87 
df: 8 
p = 0.000 
Tests cross country difference in 
self-reported intentional non-
adherence, as a proportion of all 
self-reported non-adherence 
ANOVA F-test: 106.08 – 115.49† 
(Complete case F: 103.24) 
p = 0.000 
*95% CI of mean based on imputed data 
†Range of imputation specific statistics 
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Table 3: Summary of the logistic regression model using the Morisky non-adherence as the dependent variable. Figures are reported as odds 
ratio (95% confidence interval) and exact p-values. 
 
 
Explanatory variable† 
Country 
Austria Belgium England Germany Greece Hungary Netherlands Poland Wales 
Demographics 
 Age 
0.96 
(0.93, 0.99) 
p = 0.012 
0.97 
(0.95, 1.00) 
p = 0.047 
0.98 
(0.94, 1.03) 
p = 0.431 
0.97 
(0.94, 1.01) 
p = 0.012 
  
0.94 
(0.91, 0.98) 
p = 0.001 
0.98 
(0.94, 1.00) 
p = 0.088 
0.97 
(0.93, 1.00) 
p = 0.037 
 Employment 
1.32 
(0.56, 3.13) 
p = 0.521 
 
3.14 (1.34, 
7.34) 
p = 0.008 
1.25 
(0.49, 3.19) 
p = 0.646 
 
2.93 (1.58, 
5.42) 
p = 0.001 
 
1.12 
(0.55, 2.27) 
p = 0.762 
0.82 
(0.37, 1.82) 
p = 0.618 
Socio-demographics / Clinical factors 
 Number of tablets 
0.97 
(0.88, 1.07) 
p = 0.502 
   
0.88 
(0.78, 0.98) 
p = 0.025 
    
 
Dosing frequency 
Once daily 
   
0.08 (0.03, 
0.26) 
p < 0.001 
     
 
Twice daily 
   
0.24 
(0.09, 0.62) 
p = 0.004 
     
 Income source 
0.72 
(0.31, 1.67) 
p = 0.445 
 
0.99 
(0.36, 2.73) 
p = 0.977 
3.83 
 (1.31, 11.18) 
p = 0.014 
    
1.08 
(0.45, 2.58) 
p = 0.864 
 
Borrowing income: 
Difficult 
  
6.26 
(1.14, 34.46) 
p = 0.035 
 
3.01 
(0.81, 11.12) 
p = 0.098 
1.30 
(0.64, 2.62) 
p = 0.469 
   
 
Neither difficult or 
easy 
  
5.28 
(0.93, 30.17) 
p = 0.061 
 
1.82 
(0.43, 7.72) 
p = 0.418 
3.36 
(1.34, 8.43) 
p = 0.010 
   
 Easy   
5.47 
(1.00, 29.77) 
p = 0.050 
 
3.08 
(0.65, 14.59) 
p = 0.157 
0.59 
(0.24, 1.47) 
p = 0.261 
   
 
Number of items 
prescribed 
1.06 
(0.95, 1.19) 
 
0.86 
(0.76, 0.97) 
0.84 
(0.70, 1.00) 
     
33 
 
p = 0.313 p = 0.017 p = 0.051 
Illness perceptions 
 Illness consequences 
0.89 
(0.81, 0.99) 
p = 0.029 
        
 Personal control 
0.94 
(0.84, 1.04) 
p = 0.230 
 
0.94 
(0.83, 1.07) 
p = 0.333 
 
0.79 
(0.66, 0.95) 
p = 0.013 
0.93 
(0.82, 1.06) 
p = 0.289 
  
0.88 
(0.79, 0.99) 
0.031 
 
Concern about 
illness 
       
0.79 
(0.68, 0.92) 
p = 0.002 
 
Theory of planned behaviour 
 Barrier     
1.28 
(1.03, 1.60) 
p = 0.028 
 
1.26 
(0.97, 1.63) 
p = 0.078 
 
0.93 
(0.72, 1.22) 
p = 0.610 
 Self efficacy 
0.79 (0.70, 
0.90) 
p < 0.001 
 
0.82 
(0.69, 0.96) 
p = 0.016 
0.62 (0.52, 
0.74) 
p < 0.001 
0.53 (0.43, 
0.67) 
p < 0.001 
0.82 
(0.71, 0.95) 
p = 0.006 
0.84 
(0.73, 0.96) 
p = 0.013 
0.81 
(0.68, 1.04) 
p = 0.111 
0.70 
(0.60, 0.82) 
p < 0.001 
0.66 
(0.56, 0.79) 
p < 0.001 
BRIGHT 
 Barriers 
1.04 
(1.00, 1.08) 
p = 0.035 
 
1.04 
(0.98, 1.10) 
p = 0.155 
 
1.05 
(1.00, 1.10) 
p = 0.061 
1.05 
(1.00, 1.10) 
p = 0.051 
 
1.06 
(1.00, 1.11) 
p = 0.034 
1.05 
(0.99, 1.11) 
p = 0.107 
 
Constant‡
 
 
133.99 
(6.92, 
2593.41) 
p = 0.001 
33.32 (4.06, 
273.37) 
p = 0.001 
11.78 
(0.17, 833.40) 
p = 0.256 
649.33 (28.07, 
15018.96) 
p < 0.001 
8.10 
(0.36, 183.93) 
p = 0.189  
4.13 
(0.49, 
35.10) 
p = 0.194 
33.71 
(1.92, 
591.49) 
p = 0.016 
320.84 
(9.36, 
10993.92) 
p = 0.001 
124.91 
(1.44, 
10848.02) 
p = 0.034 
Other predictors in 
model where p>0.05§ 
2, 18, 19, 22, 
24 
20 
6, 7, 8, 9, 15, 
16, 17, 19, 20, 
25 
 
1, 9, 10, 13, 
15, 17, 19, 20, 
25 
9, 10, 17, 
23, 26 
11, 12 
10, 13, 14, 15, 
16, 22, 25 
3, 4, 5, 15, 17, 
20, 21, 23, 25 
 
Final Model χ 2 and 
p value+ 
64.94, 78.87 
p < 0.001 
14.36,  
27.28 
p < 0.001 
104.25,  145.31 
p < 0.001 
89.41, 123.04 
p < 0.001 
76.51, 89.42 
p < 0.001 
64.02, 
81.23 
p < 0.001 
25.74, 47.98 
p < 0.001 
76.56, 120.57 
p < 0.001 
75.19, 94.15 
p < 0.001 
 
†Only Odds ratios for predictors with p<0.05 for at least one country are presented.  
‡Constant reported for all values of p 
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§Number of medical conditions (1), Number of different medicines (2), Income deciles 1-4 (3), Income deciles 5-7 (4), Income deciles 8-10 (5), Perception of income: Living 
comfortably (6), Perception of income: Coping (7), Perception of income: Finding it difficult (8), Affordability problem (9), Cost coping strategies (10), Time preference: 
long (11), Time preference: short (12), Prescriber of medicines (13), Gender of prescriber (14), Satisfaction with practitioner (15), Satisfaction with practice (16), Optimism 
(17), Timeline (18), Treatment control (19), Illness coherence (20), Emotional representations (21),  Necessity of medicines (22),  Concern about medicine (23),  Attitude 
(24),  Intention (25),  Social Support (26) 
+As χ2 cannot be pooled, we report the range of imputation specific χ2. The degrees of freedom per imputation is given by (number of variables -1).  Imputation-specific, p-
values were p < 0.001 in all cases, with the exception of 3 imputations in Belgium (which were p=0.001, 0.001, 0.002). 
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Table 4: Summary of the final regression model (all variables) using the MARS adherence dependent variable (-coefficient, 95% confidence 
intervals) 
 
Explanatory 
variable* 
Country 
Austria Belgium England Germany Greece Hungary Netherlands Poland Wales 
Demographics 
 Age 
0.01 
(-0.02, 
0.03) 
p = 0.606 
0.00 
(-0.02, 
0.03) 
p = 0.922 
0.02 
(-0.01, 0.05) 
p = 0.109 
0.02 
(-0.01, 0.04) 
p = 0.153 
  
0.03 
(0.00, 0.06) 
p = 0.026 
 
0.00 
(-0.02, 0.03) 
p = 0.976 
 Sex    
0.39 
(-0.10, 0.88) 
p = 0.119 
    
0.49 
(0.00, 0.98) 
p = 0.050 
Socio-demographic / Clinical factors 
 
Cost coping 
strategies 
-0.10 
(-0.22, 
0.01) 
p = 0.076 
-0.17 
(-0.30, -
0.06) 
p = 0.004 
-0.12 
(-0.21, -0.02) 
p = 0.020 
-0.06 
(-0.16, 0.05) 
p = 0.319 
-0.35 
(-0.42, -
0.28) 
p < 0.001 
-0.21 
(-0.28, -
0.15) 
p < 0.001 
 
-0.12 
(-0.25, 0.02) 
p = 0.094 
 
Time preference 
 Short     
7.12 
(2.14, 
12.09) 
p = 0.005 
    
Illness perceptions 
 Personal control   
0.01 
(-0.10, 0.11) 
p = 0.931 
 
-0.11 
(-0.26, 0.04) 
p = 0.144 
0.17 
(0.04, 
0.30) 
p = 0.011 
0.11 
(-0.02, 0.24) 
p = 0.102 
0.05 
(-0.24, 0.33) 
p = 0.735 
0.05 
(-0.05, 0.15) 
p = 0.348 
 
Treatment 
control 
0.26 
(0.13, 0.39) 
p < 0.001 
 
0.13 
(-0.02, 0.28) 
p = 0.095 
-0.02 
(-0.17, 0.13) 
p = 0.794 
0.08 
(-0.08, 0.24) 
p = 0.299 
-0.09 
(-0.25, 
0.07) 
p = 0.284 
 
0.11 
(-0.27, 0.50) 
p = 0.558 
0.07 
(-0.08, 0.20) 
p = 0.366 
 
Illness 
coherence 
  
-0.07 
(-0.20, 0.06) 
p = 0.274 
 
0.17 
(0.02, 0.32) 
p = 0.032 
0.08 
(-0.06, 
0.21) 
p = 0.257 
  
-0.01 
(-0.13, 0.10) 
p = 0.814 
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Theory of planned behaviour 
 Intention 
-0.09 
(-0.25, 
0.07) 
p = 0.286 
 
 
0.06 
(-0.17, 0.28) 
p = 0.623 
 
0.15 
(-0.03, 0.33) 
p = 0.112 
0.32 
(0.09, 
0.55) 
p  = 0.007 
 
-0.01 
(-0.53, 0.51) 
p = 0.971 
0.33 
(0.04, 0.62) 
p = 0.028 
 Self efficacy 
0.28 
(0.16, 0.40) 
p < 0.001 
0.19 
(0.02, 
0.36) 
p = 0.027 
0.30 
(0.17, 0.42) 
p < 0.001 
0.32 
(0.19, 0.46) 
p < 0.001 
0.39 
(0.26, 0.52) 
p < 0.001 
0.15 
0.03, 0.26 
p = 0.016 
0.25 
(0.09, 0.41) 
p = 0.002 
0.29 
(-0.03, 0.61) 
p = 0.072 
0.37 
(0.22, 0.51) 
p < 0.001 
BRIGHT 
 Barriers 
-0.04 
(-0.07, 
0.00) 
p = 0.062 
-0.01 
(-0.05, 
0.03) 
p = 0.698 
-0.04 
(-0.09, 0.01) 
p = 0.081 
-0.00 
(-0.03, 0.03) 
p = 0.893 
-0.05 
(-0.09,0.01) 
p = 0.010 
-0.07 
(-0.11, -
0.03) 
p = 0.101 
 
-0.08 
(-0.17, 0.00) 
p = 0.057 
-0.06 
(-0.11, 0.00) 
p = 0.060 
 Social Support 
-0.02 
(-0.09, 
0.04) 
p = 0.520 
 
0.00 
(-0.04, 0.05) 
p = 0.920 
  
-0.05 
(-0.10, -
0.01) 
p = 0.024 
  
0.03 
(-0.02, 0.07) 
p = 0.270 
 Constant 
18.97 
(15.83, 
22.10) 
p < 0.001 
21.72 
(19.04, 
24.40) 
p < 0.001 
17.83 
(13.96, 
21.69) 
p < 0.001 
20.15 
(17.35, 
22.96) 
p < 0.001 
19.06 
(16.32, 
21.80) 
p < 0.001 
19.76 
16.70, 
22.82) 
p < 0.001 
19.48 
(17.29, 
21.68) 
p < 0.001 
13.74 
(8.97, 18.51) 
p < 0.001 
19.37 
(15.86, 
22.88) 
p < 0.001 
Other predictors in 
model where 
p>0.05† 
2, 6, 11, 13, 
14, 20, 22, 
23 
11, 14, 20 
3, 8, 9, 10, 
11, 13, 14, 
15, 16, 17, 
18, 19, 20, 
22, 24 
13, 14, 16, 
17, 19, 20, 
22 
3, 5, 7, 8, 
10, 11, 12, 
14, 15, 17, 
19, 24 
1, 7, 10, 
13, 14, 15, 
16, 17, 19, 
20, 22, 23, 
24 
24 13, 21, 23 
3, 4, 5, 8, 11, 
13, 14, 15, 
16, 17, 19, 
20, 23, 24 
 Adjusted R2 0.2831 0.2005 0.3809 0.2223 0.6521 0.4589 0.1335 0.1482 0.3570 
 
*Only coefficients for predictors with p<0.05 for at least one country are presented.  
 
†Marital status (1), Employment (2), Dosage frequency (3), Number of medicines (4), Number of medical conditions (5), Income source (6), Total income (7), Income 
perception (8), Borrowing (9), Affordability problem (10), Health status (11), Time preference: long (12), Satisfaction with practitioner (13), Satisfaction with practice (14), 
Optimism (15), Illness consequences (16), Identity (17), Concern about illness (18), Emotional representations (19), Concern about medicine (20), Necessity of medicine 
(21), Attitude (22), Normative beliefs (23), Barriers-TPB (24) 
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Table 5: Summary of multilevel regression models for Morisky and MARS as outcome 
measures.  
 
 
 Morisky MARS 
Explanatory variable Odds Ratio 
95% 
Confidence 
Interval β-coefficient 
95% 
Confidence 
Interval 
Sex 1.22* 1.01, 1.47   
Age 0.98‡ 0.97, 0.99 0.01* 0.00, 0.02 
Employment 0.74* 0.59, 0.94   
Education   -0.34** -0.60, -0.09 
Number of medicines 0.89‡ 0.86, 0.93 0.06* 0.01, 0.10 
Dosing frequency 1.30† 1.12, 1.52 -0.24† -0.42, -0.06 
Normative beliefs 1.05* 1.01, 1.09   
Self-efficacy 0.73‡ 0.70, 0.77 0.36‡ 0.30, 0.42 
Barriers (BRIGHT) 1.70‡ 1.38, 2.09 -0.83‡ -1.10, -0.57 
Illness consequences   -0.06* -0.10, -0.01 
Personal control 0.94† 0.90, 0.97   
Treatment control   0.11† 0.04, 0.19 
Concern about illness 0.94† 0.91, 0.98   
Borrowing money 0.85† 0.78, 0.94   
Constant 34.59‡ 13.5, 88.5 19.45‡ 18.1, 20.8 
Random effects parameters Variance 
95% 
Confidence 
Interval 
Variance 
95% 
Confidence 
Interval 
Between country variance (σu2) 0.40 0.15, 1.07 2.14 0.79, 5.80 
Within country variance (σe2)   7.09 6.63, 7.57 
% variance attributable to 
differences between countries 
10.82 4.35, 24.49 23.20 10.63, 43.40 
 
*p<0.05, †p<0.01, ‡p<0.001 
For the logit model σe2 =  π2/3  
Variance partition coefficient, VPC = σu2/( σu2+ σe2) 
 
Full model specification: age, sex, education, marital status, employment, number of medical 
conditions, number of different medicines, number of tablets, dosing frequency, number of 
items prescribed, health status, affordability problem, optimism, necessities, concerns about 
medicine, attitudes, normative beliefs, barrier (theory of planned behaviour), facilitators, 
intention, self-efficacy, prescriber of medicines, gender of prescriber, satisfaction with 
practitioner, satisfaction with practice, barriers (averaged as one less collected in Wales), 
social support, illness consequences, illness timeline, personal control, treatment control, 
illness symptomaticity, concern about illness, illness coherence, emotional representations, 
income source, income perception, ease of borrowing, total income. 
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Figure 1. Percentage of complete responses according to country and item of the questionnaire. 
 
 
Abbreviations: MARS Medication Adherence Rating Scale; LOTQ Life Orientation Test; BMQ Beliefs about Medicines Questionnaire; TPB Theory of Planned Behaviour; 
EUROPEP European Task Force on Patient Evaluations of General Practice; BRIGHT Building Research Initiative Group Illness Management and Adherence in 
Transplantation; BIPQ Brief Illness Perception Questionnaire 
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